Combination of Acetylcysteine And Acebrophylline In Moderate to Severe Asthma And COPD Patients. - CARE

Mankind Pharma0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年6月26日

试验速览

暂无简介。

•1. Aged between 18 to 65
•2. Ready to sign an informed consent form or informed consent form signed by legally acceptable representatives.
•3. Moderate - severe COPD patients (FEV1- 30-80%).
•4. GINA 3-5 Asthma patients.

•1. severely ill and mentally retarded patients who cannot converse properly.
•2. Patients unable to complete the QoL questionnaire.
•3. Patients are known or thought to be hypersensitive to the study drug.
•4. History of auto-immune disease.
•5. Concurrent use of corticosteroids
•6. Any medication or indication that might point to an increased risk, associated with study participation or study drug administration, or may interfere with the interpretation of study results and, in the judgment of the study personnel, would make the subject inappropriate for inclusion.
•7. Participation in other clinical trials during study participation.
•8. Patients with a history of epilepsy, or those at risk for seizures or taking seizure drugs.
•9. Pregnant and lactating women.
•10. Patients with severe renal impairment, including those receiving dialysis.
•11. Patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities.
•12. Patients admitted to ICU.

发起方